Boosting endogenous neuroprotection in multiple sclerosis: The ASsociation of inosine and interferon β in relapsing-remitting multiple sclerosis (ASIIMS) trial

Multiple Sclerosis

Volumn 16, Issue 4, 2010, Pages 455-462

  Gonsette, Richard E ^a   Sindic, Christian ^b   D'Hooghe, Marie B ^a   De Deyn, Peter Paul ^c   Medaer, Robert ^d   Michotte, Alex ^e   Seeldrayers, Pierrette ^f   Guillaume, Daniel ^g  

^a National Multiple Sclerosis Center   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^c Algemeen Ziekenhuis Midellheim   (Belgium)

^d HASSELT UNIVERSITY   (Belgium)

^e UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^f Centre Hospitalier Universitaire de Charleroi   (Belgium)

^g Centre Neurologique et de Readaptation Fonctionnelle   (Belgium)

Author keywords

Endogenous neuroprotection; Inosine; Multiple sclerosis; Neurodegeneration; Uric acid

Indexed keywords

BETA INTERFERON; INOSINE; PLACEBO; URIC ACID; ANTIINFLAMMATORY AGENT; BETA1A INTERFERON; INTERFERON BETA SERINE; INTERFERON BETA-1B; NEUROPROTECTIVE AGENT;

ADULT; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISABILITY; DISEASE COURSE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FLU LIKE SYNDROME; GOUT; HUMAN; HYPERURICEMIA; INJECTION SITE REACTION; ISCHEMIC HEART DISEASE; KAPLAN MEIER METHOD; LITHOTRIPSY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NAUSEA; NEPHROLITHIASIS; NEUROPROTECTION; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; STROKE; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URETER STONE; URIC ACID BLOOD LEVEL; URINARY TRACT INFECTION; BELGIUM; BLOOD; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; HOSPITALIZATION; METABOLISM; MIDDLE AGED; TIME; TREATMENT OUTCOME;

ADULT; ANTI-INFLAMMATORY AGENTS; BELGIUM; DISABILITY EVALUATION; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INOSINE; INTERFERON-BETA; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NEUROPROTECTIVE AGENTS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; URIC ACID;

EID: 77954673594     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458509360547     Document Type: Article

References (48)

1. Cross AH, Manning PT, Keeling RM, Schmidt RE, Misko TP. Peroxynitrite formation within the central nervous system in active multiple sclerosis. J Neuroimmunol 1998;88:45-56.
2. Becker BF. Towards the physiological function of uric acid. Free Radic Biol Med 1993;14:615-631.
3. Gonsette RE. Neurodegeneration in multiple sclerosis: The role of oxidative stress and excitotoxicity. J Neurol Sci 2008;274:48-53.
4. Hooper DC, Spitsin S, Kean RB, et al. Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci U S A 1998;95:675-680.
5. Spitsin S, Hooper DC, Mikheeva T, Koprowski H. Uric acid levels in patients with multiple sclerosis: analysis in mono-and dizygotic twins. Mult Scler 2001;7:165-166.
6. Rentzos M, Nikolaou C, Anagnostouli M, et al. Serum uric acid and multiple sclerosis. Clin Neurol Neurosurg 2006;108:527-531.
7. Koch M, De Keyser J. Uric acid in multiple sclerosis. Neurol Res 2006;28:316-319.
8. Hooper DC, Bagasra O, Marini JC, et al. Prevention of experimental allergic encephalomyelitis by targeting nitric oxide and peroxynitrite: implications for the treatment of multiple sclerosis. Proc Natl Acad Sci U S A 1997;94:2528-2533.
9. Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant-and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A 1981;78:6858-6862.
10. Koprowski H, Spitsin SV, Hooper DC. Prospects for the treatment of multiple sclerosis by raising serum levels of uric acid, a scavenger of peroxynitrite. Ann Neurol 2001;49:139.
11. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-127.
12. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-1504.
13. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-661.
14. Freedman LS. Tables of the number of patients required in clinical trials using the logrank test. Stat Med 1982;1:121-129.
15. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
16. Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999;122:871-882.
17. Lin D, Wei L, Yang I, Ying Z. Semiparametric regression for the mean and rate functions of recurrent events. J R Statist Soc Ser B 2000;62:711-730.
18. Ramsaransing GS, Heersema DJ, De Keyser J. Serum uric acid, dehydroepiandrosterone sulphate, and apolipoprotein e genotype in benign vs. progressive multiple sclerosis. Eur J Neurol 2005;12:514-518.
19. Drulović J, Dujmovic I, Stojsavljević N, et al. Uric acid levels in sera from patients with multiple sclerosis. J Neurol 2001;248:121-126.
20. Toncev G, Milicic B, Toncev S, Samardzic G. Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction. Eur J Neurol 2002;9:221-226.
21. Sotgiu S, Pugliatti M, Sanna A, et al. Serum uric acid and multiple sclerosis. Neurol Sci 2002;23:183-188.
22. Deretzi G, Pelidou SH, Zacharakis G, Kyritsis AP. Serum levels of uric acid in patients with multiple sclerosis: a biological marker in clinical course and treatment of MS. Mult Scler 2003;9(Suppl 1):S100, P412.
23. Mostert JP, Ramsaransing GS, Heersema DJ, Heerings M, Wilczak N, De Keyser J. Serum uric acid levels and leukocyte nitric oxide production in multiple sclerosis patients outside relapses. J Neurol Sci 2005;231:41-44.
24. Guerrero AL, Martín-Polo J, Laherrán E, et al. Variation of serum uric acid levels in multiple sclerosis during relapses and immunomodulatory treatment. Eur J Neurol 2008;15:394-397.
25. Tsakiri A, Tsiantoulas D, Frederiksen J. Serum uric acid levels are decreased in patients with relapsing-remitting multiple sclerosis, in particular during relapses. Mult Scler 2008;14(Suppl 1):S289, P888.
26. Constantinescu CS, Freitag P, Kappos L. Increase in serum levels of uric acid, an endogenous antioxidant, under treatment with glatiramer acetate for multiple sclerosis. Mult Scler 2000;6:378-381.
27. Toncev G, Drakulic M, Knezevic Z. Treatment with interferon beta 1b (Betaferon) and serum uric acid levels: two year follow-up. Mult Scler 2007;13(Suppl 2):S90, P305.
28. Handouk Y, Angeleri VA, Danni M, De Riso S, Provinciali L. Increase of serum uric acid levels in multiple sclerosis during treatment with natalizumab. Mult Scler 2008;14(Suppl 1):S281, P888.
29. Scott GS, Spitsin SV, Kean RB, Mikheeva T, Koprowski H, Hooper DC. Therapeutic intervention in experimental allergic encephalomyelitis by administration of uric acid precursors. Proc Natl Acad Sci U S A 2002;99:16303-16308.
30. Church WH, Ward VL. Uric acid is reduced in the substantia nigra in Parkinson's disease: effect on dopamine oxidation. Brain Res Bull 1994;33:419-425.
31. Fitzmaurice PS, Ang L, Guttman M, Rajput AH, Furukawa Y, Kish SJ. Nigral glutathione deficiency is not specific for idiopathic Parkinson's disease. Mov Disord 2003;18:969-976.
32. Hensley K, Maidt ML, Yu Z, Sang H, Markesbery WR, Floyd RA. Electrochemical analysis of protein nitrotyrosine and dityrosine in the Alzheimer brain indicates region-specific accumulation. J Neurosci 1998;18:8126-8132.
33. Beal MF, Matson WR, Storey E, et al. Kynurenic acid concentrations are reduced in Huntington's disease cerebral cortex. J Neurol Sci 1992;108:80-87.
34. Langemann H, Kabiersch A, Newcombe J. Measurement of low-molecular-weight antioxidants, uric acid, tyrosine and tryptophan in plaques and white matter from patients with multiple sclerosis. Eur Neurol 1992;32:248-252.
35. van Horssen J, Schreibelt G, Drexhage J, et al. Severe oxidative damage in multiple sclerosis lesions coincides with enhanced antioxidant enzyme expression. Free Radic Biol Med 2008;45:1729-1737.
36. Kieseier BC, Hartung HP. Interferon-beta and neuroprotection in multiple sclerosis-facts, hopes and phantasies. Exp Neurol 2007;203:1-4.
37. Schwartz M, London A, Shechter R. Boosting T-cell immunity as a therapeutic approach for neurodegenerative conditions: the role of innate immunity. Neuroscience 2009;158:1133-1142.
38. Barnett MH, Parratt JD, Cho ES, Prineas JW. Immunoglobulins and complement in postmortem multiple sclerosis tissue. Ann Neurol 2009;65:32-46.
39. Nguyen T, Nioi P, Pickett CB. The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J Biol Chem 2009;284:13291-13295.
40. Vamos E, Pardutz A, Klivenyi P, Toldi J, Vecsei L. The role of kynurenines in disorders of the central nervous system: Possibilities for neuroprotection. J Neurol Sci 2009;283:21-27.
41. Aboul-Enein F, Rauschka H, Kornek B, et al. Preferential loss of myelin-associated glycoprotein reflects hypoxia-like white matter damage in stroke and inflammatory brain diseases. J Neuropathol Exp Neurol 2003;62:25-33.
42. Mhâille AN, McQuaid S, Windebank A, et al. Increased expression of endoplasmic reticulum stress-related signalling pathway molecules in multiple sclerosis lesions. J Neuropathol Exp Neurol 2008;67:200-211.
43. Baker D, Pryce G. The endocannabinoid system and multiple sclerosis. Curr Pharm des 2008;14:2326-2336.
44. Spitsin S, Hooper DC, Leist T, et al. Inactivation of peroxynitrite in multiple sclerosis patients after oral administration of inosine may suggest possible approaches to therapy of the disease. Mult Scler 2001;7:313-319.
45. Toncev G, Milicic B, Perovic S, Toncev S, Zlatic G, Knecevic Z. Inosine in the treatment of multiple sclerosis: an open-label study in 32 patients. Neurology 2005;94(Suppl 1):A385, poster P06.151.
46. Markowitz CE, Spitsin S, Zimmerman V, et al. The treatment of multiple sclerosis with inosine. J Altern Complement Med 2009;15:619-625.
47. Gilgun-Sherki Y, Melamed E, Offen D. The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J Neurol 2004;251:261-268.
48. Mirshafiey A, Mohsenzadegan M. Antioxidant therapy in multiple sclerosis. Immunopharmacol Immunotoxicol 2009;31:13-29.